Daphne Karydas
Known title: DirectorCIK: 0001816952
Associated companies
Transaction History
| MLYS | ▲ Buy | Option Exercise | 3,000 | $36K | 9/15/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 3,000 | $86K | 9/15/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 3,000 | $36K | 6/17/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 3,000 | $75K | 6/17/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 3,000 | $36K | 3/31/2026 | View on chart |
| MLYS | ▼ Sell | Open Market | 3,000 | $75K | 3/31/2026 | View on chart |
| MLYS | ▲ Buy | Grant | 6,200 | $0 | 2/19/2026 | View on chart |
| MLYS | ▲ Buy | Option Exercise | 15,000 | $153K | 11/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 10,115 | $463K | 11/13/2025 | View on chart |
| MLYS | ▼ Sell | Open Market | 4,885 | $226K | 11/13/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views
Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.
Mineralys Presents Phase 3 Data, Receives Mixed Analyst Views. Mineralys Therapeutics presented new data from its pivotal Phase 3 Launch-HTN study at the American Heart Association Hypertension Scientific Sessions 2026. Following this update, UBS initiated coverage with a Neutral rating and a $29 price target, while HC Wainwright reiterated a Buy rating with a $56 target. The stock is currently trading near its support level, reflecting the divided analyst opinions on the company's outlook.